Siga receives £20 million to develop smallpox antiviral
This article was originally published in Scrip
Siga Technologies has received a further $20 million to accelerate the development of the company's smallpox antiviral ST-246. The funding, from the US National Institute of Allergy and Infectious Disease (NIAID), a division of the National Institutes of Health, adds to Siga's existing $16.5 million contract with the NIAID, which itself obtained the funding from the Department of Health and Human Services. The funding will help Siga to begin commercial manufacturing of ST-246 in a timely manner, Dr Dennis Hruby, the company's chief scientific officer, said. Siga received a $963,000 grant from the NIAID to help fund its dengue fever antiviral programme earlier this month (Scrip Online, September 16th, 2008).
You may also be interested in...
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.